Fewer than 50 percent of preclinical research studies, conducted at a cost of $28 billion per year, are reproducible. Rigor in bioanalytical method validation is emerging in the form of a global standard: preclinical studies are increasingly outsourced (by some estimates, more than half of the time) and senior scientists add the management of an offshore team to their duties.
How can software increase the reproducibility of preclinical research studies amid the shift towards outsourcing and the convergence of regulation and expectations?
Both at the sponsor and the contract service provider, value takes the form of price, delivery time, reputation, transparency and security — the kind of efficiencies a software investment is expected to provide.
This webinar will examine how the deployment of tools in a unit operations or “Workflow-as-a-Service” context can enable reproducible, consistent and transparent work at the scientist bench — while delivering sponsor value at the same time.
Graeme Dennis, Commercial Director, Preclinical Pharma, IDBS
Graeme Dennis joined IDBS as the commercial director of preclinical pharma in 2018. Prior to IDBS, Graeme held scientific informatics roles in academia and industry, including Accenture, Dotmatics and Vanderbilt University Medical Center. He is interested in systems that help organizations decouple data from its systems of acquisition and use.
Who Should Attend?
Senior-level pharma R&D scientists and leaders involved in:
- Preclinical Studies
- Regulatory Compliance
- Project Management
- Operational Oversight
What You Will Learn
Participants will learn about:
- What sets apart a successful preclinical informatics implementation
- How the software market has responded to the shift to outsourcing
- Where competitive advantage may be gained for outsourced pharma
- Why software can help improve reproducibility in preclinical studies
Providing the world’s best cloud-based, research and development data management technology and solutions in a scientific informatics platform.
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data.
Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989 and privately held until 2017, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS employs over 250 staff across the world and serving over 50,000 researchers in 25 countries – including 22 of the top 25 pharmaceutical companies.
IDBS was acquired by the Danaher Group and joined their Life Sciences platform in late October 2017. IDBS will help provide the foundation for a portfolio of life sciences informatics and knowledge management solutions that will accelerate the speed of discovering, developing and producing new drugs and therapies.